Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

by Zacks Equity Research

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised

by Zacks Equity Research

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

Teva Pharmaceutical Industries Ltd. (TEVA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated

by Zacks Equity Research

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit

by Zacks Equity Research

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

by Zacks Equity Research

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.

Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate

by Zacks Equity Research

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why

by Zacks Equity Research

Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.

Alkermes (ALKS) Grants Teva License to Market Generic Drug

by Zacks Equity Research

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

by Zacks Equity Research

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

TEVA to Pay $250 Million to Settle Price-Fixing Charges

by Zacks Equity Research

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical

by Zacks Equity Research

Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

by Zacks Equity Research

TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.

Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth

by Zacks Equity Research

Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.

Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings

by Zacks Equity Research

The headline numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical

by Zacks Equity Research

Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Macro Headwinds

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

by Zacks Equity Research

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

Compared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Embecta (EMBC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.

Charles River (CRL) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q1.

GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings

by Zacks Equity Research

Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.